Found: 7
Select item for more details and to access through your institution.
AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.
- Published in:
- Cancer Reports, 2023, v. 6, n. 10, p. 1, doi. 10.1002/cnr2.1881
- By:
- Publication type:
- Article
Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 1, p. 41, doi. 10.1002/cncr.35005
- By:
- Publication type:
- Article
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 6, p. 2188, doi. 10.3390/jcm12062188
- By:
- Publication type:
- Article
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 24, p. 7418, doi. 10.3390/jcm11247418
- By:
- Publication type:
- Article
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
- Published in:
- Hematological Oncology, 2024, v. 42, n. 2, p. 1, doi. 10.1002/hon.3259
- By:
- Publication type:
- Article
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 6, p. 922, doi. 10.1111/ejh.14105
- By:
- Publication type:
- Article
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data.
- Published in:
- Healthcare (2227-9032), 2023, v. 11, n. 10, p. 1479, doi. 10.3390/healthcare11101479
- By:
- Publication type:
- Article